Literature DB >> 10672264

Discordance between traditional pathologic and energy metabolic changes in very early Alzheimer's disease. Pathophysiological implications.

S Minoshima1, D J Cross, N L Foster, T R Henry, D E Kuhl.   

Abstract

These results suggest that neither the loss of entorhinal efferents nor cholinergic deficit explains all the metabolic features seen in very early AD. Given recent immunohistological evidence of massive glutamatergic synaptic alteration in early AD cortex and insights into neuronal and glial mechanisms of glucose metabolism, very early metabolic changes in AD probably reflect a significant impairment of glycolytic activities in the cortico-cortical glutamatergic systems in a preclinical stage of the disease. However, the exact mechanisms of such impairment in these neurons are yet to be determined.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10672264     DOI: 10.1111/j.1749-6632.1999.tb07852.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  12 in total

1.  Loss of olfactory tract integrity affects cortical metabolism in the brain and olfactory regions in aging and mild cognitive impairment.

Authors:  Donna J Cross; Yoshimi Anzai; Eric C Petrie; Nathalie Martin; Todd L Richards; Kenneth R Maravilla; Elaine R Peskind; Satoshi Minoshima
Journal:  J Nucl Med       Date:  2013-06-26       Impact factor: 10.057

2.  Multivariate and univariate neuroimaging biomarkers of Alzheimer's disease.

Authors:  Christian Habeck; Norman L Foster; Robert Perneczky; Alexander Kurz; Panagiotis Alexopoulos; Robert A Koeppe; Alexander Drzezga; Yaakov Stern
Journal:  Neuroimage       Date:  2008-02-14       Impact factor: 6.556

3.  Neuroimaging of individuals with Down's syndrome at-risk for dementia: evidence for possible compensatory events.

Authors:  R J Haier; K Head; E Head; I T Lott
Journal:  Neuroimage       Date:  2007-10-12       Impact factor: 6.556

4.  Grey matter hypometabolism and atrophy in Parkinson's disease with cognitive impairment: a two-step process.

Authors:  Rafael González-Redondo; David García-García; Pedro Clavero; Carmen Gasca-Salas; Reyes García-Eulate; José L Zubieta; Javier Arbizu; José A Obeso; María C Rodríguez-Oroz
Journal:  Brain       Date:  2014-06-20       Impact factor: 13.501

5.  Phosphoinositides: Two-Path Signaling in Neuronal Response to Oligomeric Amyloid β Peptide.

Authors:  Romina María Uranga; Natalia Paola Alza; Melisa Ailén Conde; Silvia Susana Antollini; Gabriela Alejandra Salvador
Journal:  Mol Neurobiol       Date:  2016-04-14       Impact factor: 5.590

6.  Spatial correlation between brain aerobic glycolysis and amyloid-β (Aβ ) deposition.

Authors:  Andrei G Vlassenko; S Neil Vaishnavi; Lars Couture; Dana Sacco; Benjamin J Shannon; Robert H Mach; John C Morris; Marcus E Raichle; Mark A Mintun
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-13       Impact factor: 11.205

7.  Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings.

Authors:  Eric C Petrie; Donna J Cross; Douglas Galasko; Gerard D Schellenberg; Murray A Raskind; Elaine R Peskind; Satoshi Minoshima
Journal:  Arch Neurol       Date:  2009-05

Review 8.  Functional neuroimaging in Alzheimer's disease.

Authors:  Hiroshi Matsuda
Journal:  Radiat Med       Date:  2006-05

9.  Mechanisms underlying fatigue: a voxel-based morphometric study of chronic fatigue syndrome.

Authors:  Tomohisa Okada; Masaaki Tanaka; Hirohiko Kuratsune; Yasuyoshi Watanabe; Norihiro Sadato
Journal:  BMC Neurol       Date:  2004-10-04       Impact factor: 2.474

10.  Bioinformatics analysis of differentially expressed genes and identification of an miRNA-mRNA network associated with entorhinal cortex and hippocampus in Alzheimer's disease.

Authors:  Haoming Li; Linqing Zou; Jinhong Shi; Xiao Han
Journal:  Hereditas       Date:  2021-07-09       Impact factor: 3.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.